US FDA revokes authorization for four COVID antibody drugs

Reuters2024-12-24
UPDATE 1-US FDA revokes authorization for four COVID antibody drugs

Adds background throughout

Dec 23 (Reuters) - The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based drugs, including those from Eli Lilly LLY.N and Regeneron REGN.O.

The shelf life of the drugs had expired and they had not been authorized for administration to patients for more than a year due to the circulation of non-susceptible variants, the FDA said in letters dated earlier this month and posted on its website on Monday.

The FDA revoked the authorization for Lilly's bebtelovimab, AstraZeneca's AZN.L Evusheld, GSK's GSK.L sotrovimab and Regeneron's REGEN-COV.

The companies also do not intend to offer the products in the U.S. anymore, according to the FDA.

The FDA said the companies would notify customers and providers about the revocation with instructions for product destruction or return.

(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri and Vijay Kishore)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment